These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32687639)

  • 21. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
    Asero R
    Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
    [No Abstract]   [Full Text] [Related]  

  • 22. Ligelizumab for chronic spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.
    Shaker M; Oppenheimer J; Wallace D; Lang DM; Rambasek T; Dykewicz M; Greenhawt M
    J Allergy Clin Immunol Pract; 2020; 8(7):2360-2369.e1. PubMed ID: 31751758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
    Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels.
    Altrichter S; Hawro T; Hänel K; Czaja K; Lüscher B; Maurer M; Church MK; Baron JM
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):454-5. PubMed ID: 25371135
    [No Abstract]   [Full Text] [Related]  

  • 27. Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.
    Sussman G; Hébert J; Gulliver W; Lynde C; Yang WH; Papp K; Gooderham M; Chambenoit O; Khalil S; DeTakacsy F; Vieira A; Rihakova L
    J Allergy Clin Immunol Pract; 2020; 8(7):2372-2378.e5. PubMed ID: 32272284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
    Exposito-Serrano V; Curto-Barredo L; Aguilera Peiro P; Gómez Armayones S; Serra-Baldrich E; Spertino J; Bonfill Ortí M; Figueras Nart I; Melé-Ninot G; Baliu-Piqué C; Sala Cunill A; Labrador-Horrillo M; Guilabert Vidal A; Fernández Chico N; Giménez-Arnau AM
    Br J Dermatol; 2021 Jan; 184(1):167-168. PubMed ID: 32730636
    [No Abstract]   [Full Text] [Related]  

  • 29. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective omalizumab interval prolongation in the treatment of chronic urticaria.
    Alizadeh Aghdam M; Pieterse RH; Kentie PA; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020; 8(10):3667-3668.e1. PubMed ID: 32679351
    [No Abstract]   [Full Text] [Related]  

  • 31. Short courses of ciclosporin can induce long remissions in chronic spontaneous urticaria.
    Alves F; Calado R; Relvas M; Gomes T; Gonçalo M
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e645-e646. PubMed ID: 35344624
    [No Abstract]   [Full Text] [Related]  

  • 32. Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study.
    Song XT; Chen YD; Yu M; Liu B; Zhao ZT; Maurer M
    Allergy; 2021 Apr; 76(4):1271-1273. PubMed ID: 33275779
    [No Abstract]   [Full Text] [Related]  

  • 33. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
    Sánchez J; Alvarez L; Cardona R
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
    Agache I; Rocha C; Pereira A; Song Y; Alonso-Coello P; Solà I; Beltran J; Posso M; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong P; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2021 Jan; 76(1):59-70. PubMed ID: 32767573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria.
    Nettis E; Di Leo E; Foti C; Cegolon L; Vacca A
    J Am Acad Dermatol; 2018 Jun; 78(6):1211-1213. PubMed ID: 29203434
    [No Abstract]   [Full Text] [Related]  

  • 39. Using National Registries to Identify Targeted Therapies for Refractory Urticaria.
    Khan S; Michaelis LJ; Dawson TC; Thusby-Pelham A; Pur Özyiğit L; Krishna MT; Erlewyn-Lajeunesse M
    Int Arch Allergy Immunol; 2021; 182(5):459-460. PubMed ID: 33690233
    [No Abstract]   [Full Text] [Related]  

  • 40. Scratch pleasurability is high in chronic spontaneous urticaria.
    Labib A; Yap QV; Smith P; Yosipovitch G
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3337-3338.e1. PubMed ID: 35973524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.